Welcome to our dedicated page for Atrium Therapeutics SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atrium Therapeutics filings document the corporate transition that created the current RNA issuer and the related Avidity Biosciences merger, separation and listing records. The filing set includes 8-K material-event reports, shareholder voting disclosures, separation and merger agreement records, capital-structure information and a Form 25 covering removal of Avidity common stock from Nasdaq listing and registration.
Regulatory disclosures tied to the symbol also cover governance matters, operating and financial results, clinical or regulatory updates and security-structure information. As an independent biopharmaceutical company, Atrium's filings center on its RNA therapeutics platform, precision cardiology pipeline, collaboration economics, equity compensation and public-company reporting obligations.
Form 144 summary for Avidity Biosciences (RNA): The filing notifies a proposed sale of 30,914 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,182,769.64, scheduled for 08/06/2025. The securities were acquired as Performance Stock Units from the issuer on 12/17/2024 (amount 30,914; date of payment listed as 12/17/2024; nature of payment: N/A). The filing reports "Nothing to Report" for securities sold in the past three months. Several filer identification and notice fields (CIK, submission contact name, date of notice) are blank or not provided in the document, limiting disclosure.